Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immunobridging study of recombinant 9-valent HPV vaccine versus recombinant trivalent HPV vaccine in healthy Chinese women aged 18-45 years
CTR20252167Phase 3Active
- Sponsor
- Beijing Health Guard
- Start
- Aug 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine, Walrinvax in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), anal intraepithelial neoplasia (AIN), sponsored by Beijing Health Guard. Started Aug 2025; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccineWalrinvax
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on CTR20252167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252167.